Kanjinti (trastuzumab) | Amgen Biosimilars | Amgen

You are leaving Kanjinti.EU website and entering another Amgen website

You are leaving Kanjinti.EU website and entering another Amgen website

You are now leaving Kanjinti.EU
Amgen does not endorse or accept liability for sites controlled by third parties

Return to previous page Continue

Countries ▼

INTRODUCING KANJINTI®
THE TRASTUZUMAB BY AMGEN
For treatment of HER2+ breast and metastatic gastric cancer patients1

BEHIND KANJINTI® AMGEN’S EXPERTISE DELIVERS CONFIDENCE AND RELIABILITY

Amgen’s expertise
KANJINTI® is backed by nearly 4 decades of Amgen's experience designing and developing biologics2
Read More ►
Totality of evidence
KANJINTI® demonstrated biosimilarity through comprehensive totality of evidence
Read More ►
LILAC study
The only study with switch evidence in a sensitive patient population
Read More ►
2 vial sizes
KANJINTI® is the only trastuzumab to offer a 420 mg vial (in addition to a 150 mg vial)
Read More ►
Patient support
Amgen's continuous commitment to provide medical education and support is extended to KANJINTI® patients
Read More ►

1. KANJINTI® Summary of Product Characteristics, May 2018. https://www.ema.europa.eu/en/documents/product-information/kanjinti-epar-product-information_en.pdf.
2. https://www.amgenbiosimilars.com/ (accessed May 2018).

banner

The information contained in this website is for European healthcare professionals only

I understand and confirm I am an EU healthcare professional
Read more >
I am not an EU healthcare professional
Read more >
▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.